Late Cardiac Toxicity After Anthracyclines and Radiotherapy for Lymphoma-A Regression Analysis of Dose-Response. [PDF]
Hematol OncolNygård L +4 more
europepmc +1 more source
Risk of cardiovascular disease and death in patients with breast cancer receiving anthracycline-based therapy: A retrospective cohort study. [PDF]
PLoS OneLim YC, Lee YJ, Ha IH, Lee YS.
europepmc +1 more source
Reply: Trastuzumab Cardiotoxicity: No Need for Ejection Fraction Monitoring Without Prior Anthracycline Exposure. [PDF]
JACC CardioOncolAli A, Deswal A.
europepmc +1 more source
Oncologic Outcomes and Safety of Neoadjuvant Treatment with Anthracyclines Versus Anthracycline-Free Regimens in HER2-Positive Early Breast Cancer in a Colombian Cancer Center: An Observational, Analytical, Retrospective Study. [PDF]
Cancers (Basel)Acevedo-Ramos A +2 more
europepmc +1 more source
Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/HER2-negative breast cancer. [PDF]
Ann OncolChen N +9 more
europepmc +1 more source
Evaluation of Cardiotoxicity in Lymphoproliferative Patients Treated With Anthracycline and Bruton's Tyrosine Kinase Inhibitor-Based Regimens. [PDF]
CureusBonsu A.
europepmc +1 more source
TNF/TNF-R1 pathway is involved in doxorubicin-induced acute sterile inflammation [PDF]
, 2013 Aaes, Tania Love +8 more
core +1 more source
Anthracycline- and HER2-induced cardiotoxicity: mechanisms, current strategies, and the emerging role of dapagliflozin as a targeted cardioprotective agent. [PDF]
CardiooncologySaeed HA, Mohammed Ali NA, Othman RT.
europepmc +1 more source
Cardiovascular Care in Pediatric Cancer Survivors: Updates on Risk, Prevention, and Therapies. [PDF]
Curr Treat Options OncolLim HM +4 more
europepmc +1 more source